Last reviewed · How we verify
NCT00507702
Identification of Key Blood Molecular Markers for Immunotherapy
trial testing phlebotomy in Squamous Cell Carcinoma in 191 participants. Terminated before completion.
25 February 2015
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 191 |
| Start date | 6 July 2006 |
| Primary completion | 25 February 2015 |
| Estimated completion | 25 February 2015 |
| Sites | 1 location across United States |
Drugs / interventions tested
- phlebotomy
Conditions studied
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
- Adenocarcinoma — all drugs for Adenocarcinoma →
- Neoplasms — all drugs for Neoplasms →
Sponsor
Stanford University
Who can join
18 and older, any sex, with Squamous Cell Carcinoma or Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00507702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of phlebotomy
Trials testing the same drug.
- NCT05396170 — Effect of Phlebotomy on Heartrate in Polycythemia Patients · recruiting
- NCT05064267 — Hemostatic Profiles in Pediatric CKD · completed
Other recruiting trials for Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
- NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain · NA · recruiting
- NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00507702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 18 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00507702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing